 | 
 | |
CU-NP is currently in preclinical development for the potential treatment of a number of cardiovascular and renal diseases.
The compound, also a natriuretic peptide, was designed by researchers at Mayo Clinic to combine the favorable hemodynamic venodilating effects of CNP generated via NPR-B receptor agonism, with the beneficial renal effects generated via NPR-A receptor agonism.
In vivo studies of CU-NP have shown it to:
- Increase natriuresis, diuresis, and glomerular filtration rate (GFR) in a dose dependent manner
- Decrease cardiac filling pressure
- Inhibit the renin-angiotensin system without inducing significant hypotension.
| |
|
